GLOW Prescribed

REFERENCES · CITED RECORD

The cited literature behind the GLOW blend

Every GLOW peptide claim on this site is sourced. The constituent studies, the 2025-2026 reviews, and the FDA regulatory sources are listed below with DOIs, PMIDs, and direct links.

Read the researchWhere GLOW access stands

How to read this list

These are the GLOW peptide references the site draws on, grouped by what they support. Every quantitative claim on the site maps to one of the numbered entries below, and the blend itself has no trial entry because none exists [9]. The list is organized in three groups: the constituent literature, the recent reviews that weigh the human evidence, and the FDA regulatory sources.

Constituent literature (1-8)

These eight entries are the published evidence on the individual peptides that make up GLOW. References 1 and 2 are Pickart's GHK-Cu reviews covering collagen, elastin and glycosaminoglycan synthesis and the broader tissue-remodeling profile [1][2]. References 3 and 4 are the BPC-157 studies — the transected-tendon healing model and the VEGFR2 angiogenesis work [3][4]. References 5, 6 and 7 are the thymosin beta-4 / TB-500 record: the rat wound-healing study with the re-epithelialization figures, the multi-functional regenerative review, and the crystallographic structure establishing actin sequestration [5][6][7]. Reference 8 is the controlled hair-growth trial of a 5-ALA-plus-GHK topical complex [8].

Recent reviews on the human evidence (9-10)

References 9 and 10 are the 2025-2026 reviews that frame the human-data picture. Reference 9 is the 2026 Sports Medicine review naming BPC-157, TB-500 and GHK-Cu together and concluding that such unapproved peptides show animal-model promise but scarce human safety data and potential for harm [9]. Reference 10 is the 2025 narrative review classifying BPC-157 as investigational pending well-designed clinical trials [10].

FDA and authoritative regulatory sources (11-15)

References 11 through 15 are the FDA pages behind the GLOW legal status and 503A category statements. They cover the 503A/503B compounding framework, the specific Category 2 entries for BPC-157, TB-500 and injectable GHK-Cu, the July 23-24, 2026 advisory-committee agenda, the January 2025 interim-policy guidance, and the cosmetic-versus-drug distinction for Copper Tripeptide-1. Each FDA page was verified loading and containing the cited text on 2026-05-29.

  1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. ↗
  2. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. ↗
  3. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21:976-983. ↗
  4. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95:323-333. ↗
  5. Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. ↗
  6. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. ↗
  7. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO Journal. 2004;23(18):3599-3608. ↗
  8. Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016;28(4):438-443. ↗
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. ↗
  10. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. ↗
  11. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov (verified 2026-05-29). ↗
  12. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2 entries for BPC-157; "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500"; and "GHK-Cu (for injectable routes of administration)"; effective 2023-09-29). FDA.gov (verified 2026-05-29). ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500 and MOTs-C listed as substances being considered for inclusion on the 503A Bulks List). FDA.gov (verified 2026-05-29). ↗
  14. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance finalized January 2025). FDA.gov (verified 2026-05-29). ↗
  15. U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved but Are FDA-Regulated (basis for the cosmetic Copper Tripeptide-1 vs injectable-drug distinction). FDA.gov (verified 2026-05-29). ↗